Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
ATOS
ATOS
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
ATOS News
Atossa Therapeutics Reports Q1 2026 Financial Results and Updates
2d ago
PRnewswire
Atossa Therapeutics Q1 Financial Results
2d ago
seekingalpha
Atossa Announces KARISMA Trial Results for Endoxifen in Breast Cancer Prevention
4d ago
PRnewswire
Atossa Reports Positive Results from Endoxifen Clinical Trial for Breast Cancer Risk Reduction
4d ago
Newsfilter
Atossa's Drug Receives Rare Pediatric Disease Designation
6d ago
stocktwits
Atossa Secures Rare Pediatric Disease Designation for (Z)-endoxifen
6d ago
PRnewswire
Atossa Secures Rare Pediatric Disease Designation for (Z)-endoxifen
6d ago
Newsfilter
Atossa Therapeutics Reports FY Losses
Mar 26 2026
seekingalpha
ATOS Shares Decline Post-Market Following Earnings Disappointment — CEO Focuses on Innovative Applications for Experimental Cancer Treatment
Mar 25 2026
stocktwits
Atossa Therapeutics Reports 2025 Financial Results and Updates
Mar 25 2026
PRnewswire
Atossa Therapeutics Reports 2025 Financial Results and Corporate Developments
Mar 25 2026
Newsfilter
ATOSSA THERAPEUTICS ANNOUNCES 2025 FOURTH QUARTER AND YEAR-END FINANCIAL RESULTS ALONG WITH A CORPORATE UPDATE
Mar 25 2026
moomoo
Biotech Investment Revives as Institutional Capital Flows Back
Mar 19 2026
Globenewswire
Atossa Appoints New Medical Directors to Enhance R&D Efforts
Mar 19 2026
Newsfilter
Atossa Therapeutics Provides Strategic Update on Clinical Progress and Future Directions
Feb 11 2026
PRnewswire
Atossa Therapeutics Provides Update on Clinical Progress and FDA Feedback
Feb 11 2026
Newsfilter
Show More News
